UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050340
Receipt number R000057325
Scientific Title Anti-wrinkle effect of serum containing "Human Adipose Derived Mesenchymal Cell Exosomes" : single blinded study
Date of disclosure of the study information 2023/02/15
Last modified on 2023/08/16 15:24:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Anti-wrinkle effect of serum containing "Human Adipose Derived Mesenchymal Cell Exosomes"

Acronym

ReZARD serum study

Scientific Title

Anti-wrinkle effect of serum containing "Human Adipose Derived Mesenchymal Cell Exosomes" : single blinded study

Scientific Title:Acronym

Anti-wrinkle effect of serum containing "Human Adipose Derived Mesenchymal Cell Exosomes"

Region

Japan


Condition

Condition

Healthy adult female

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Influence to the wrinkles when an adult female used test articles serum for 4 weeks, is estimated

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Device evaluation

Key secondary outcomes

Subjective evaluation


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Use "test article 1" for 4 weeks

Interventions/Control_2

Use "test article 2" for 4 weeks

Interventions/Control_3

Do not use any test articles

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

35 years-old <=

Age-upper limit

59 years-old >=

Gender

Female

Key inclusion criteria

1. Subjects whose wrinkle class in the outer corner is 1 to 3
2. Subjects whose skin is dry
3. Subjects with blemishes, pigmentation, or sagging of the face

Key exclusion criteria

1.Pregnant women, those who may be pregnant, and those who are breastfeeding
2.Subjects who work night shifts or day and night shifts
3.Subjects who need help from others and are unable to walk independently
4.Participating in other clinical trials
5.Factors that may affect the test results (disease such as atopic dermatitis and urticaria, inflammation, eczema, trauma, acne, cheeks with a diameter of 5 cm or more) on the test site (both cheeks) Tumor warts, etc., or traces thereof)
6.Subjects who are judged by the investigator to be unsuitable for participation in this study

Target sample size

36


Research contact person

Name of lead principal investigator

1st name Takeshi
Middle name
Last name Kaneko

Organization

Japan Clinical Trial Association

Division name

N.A.

Zip code

1600022

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

TEL

0364574666

Email

info@yakujihou.org


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Kaneko

Organization

Japan Clinical Trial Association

Division name

N.A.

Zip code

1600022

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

TEL

0364574666

Homepage URL


Email

info@yakujihou.org


Sponsor or person

Institute

Japan Clinical Trial Association

Institute

Department

Personal name



Funding Source

Organization

Candee, Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Pharmaceutical Law Wisdoms

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

Tel

0364574911

Email

master@yakujihou.net


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 02 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

40

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 01 Month 04 Day

Date of IRB

2023 Year 02 Month 02 Day

Anticipated trial start date

2023 Year 02 Month 16 Day

Last follow-up date

2023 Year 05 Month 12 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 02 Month 14 Day

Last modified on

2023 Year 08 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057325


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name